Laboratory Testing Before Initiating Campral (Acamprosate)
No specific laboratory tests are required before starting acamprosate, but renal function assessment is essential because the drug is contraindicated in severe renal impairment.
Renal Function Assessment
Creatinine clearance (CrCl) must be evaluated before initiating therapy, as acamprosate is eliminated entirely unchanged through the kidneys and requires dose adjustment or contraindication based on renal function 1, 2.
Dose reduction is recommended for patients with moderate renal impairment (CrCl 30-50 mL/min), while acamprosate is contraindicated in severe renal insufficiency (CrCl <30 mL/min) 3, 2.
The drug undergoes no hepatic metabolism and is excreted 50% unchanged in urine, with the remainder possibly eliminated through biliary excretion 2.
Hepatic Function Considerations
No baseline liver function tests are required because acamprosate is not metabolized by the liver and has demonstrated no hepatotoxicity in clinical use 1.
Acamprosate is particularly suitable for patients with alcohol-related liver disease, including those with cirrhosis, as it has been shown safe even in patients with Child-Pugh B or C cirrhosis 1, 4, 5.
The pharmacokinetics remain unchanged in patients with hepatic insufficiency or chronic alcoholism, making it safer than alternatives like baclofen in cirrhotic patients 2, 5.
Other Baseline Assessments
Body weight should be documented to determine appropriate dosing: patients weighing ≥60 kg receive 666 mg three times daily (1,998 mg/day total), while those <60 kg receive approximately one-third lower doses (~1,332 mg/day) 1.
No routine monitoring of clinical chemistry tests or vital signs is required during treatment, as clinical trials showed no clinically meaningful differences in these parameters between acamprosate and placebo groups 3.
Common Pitfall to Avoid
The primary clinical error is failing to assess renal function before prescribing acamprosate, which can lead to drug accumulation and potential toxicity in patients with unrecognized kidney disease 3, 2. Unlike other alcohol use disorder medications, hepatic function is not a concern with acamprosate 1.